Moores Cancer Center/UCSD Medical center

Site:	Moores Cancer Center/UCSD Medical center
Address:
City:	La Jolla
State:	CA
Zip:	92093
Country:	USA

9 trials at this site

Phase	Trial	Trial Status	Site Status [asc]	Drug	NCT#
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT05208047
3	A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)	Recruiting	Active	Ripretinib	NCT05734105
2	Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor	Active, not recruiting	Active	Temozolomide	NCT03556384
1	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Recruiting	Active	INBRX-109 + Temozolomide	NCT03715933
3	Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)	Completed	Closed	Nilotinib or Imatinib	NCT00785785
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Closed	Imatinib	NCT00867113
2	A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors	Ongoing, but not recruiting	Closed	MEK162 + BYL719	NCT01449058
2	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	Active, not recruiting	Closed	Entrectinib	NCT02568267